Back to results
US 10,869,931 B2Granted
Polyethylene glycol-modified angiogenesis inhibitor HM-1 and application thereof
AssigneeNanjing Anji Biological Technology Co., Ltd.
InventorHanmei Xu
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNanjing Anji Biological Technology Co., Ltd.
InventorHanmei Xu
Estimating the term…
A polyethylene glycol-modified angiogenesis inhibitor HM-1 and its application are disclosed. The polypeptide sequence is mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO: 1), and mPEG . . . is chosen from mPEG-SC, mPEG2-NHS, mPEG-ALD or mPEG-bALD, with a molecular weight range of 500˜40000. The polypeptide has been modified by polyethylene glycol, has the capacity to inhibit vascular endothelial cell migration and integrin affinity and binding, and can be used for the prevention and treatment of tumors, various types of inflammation, and neovascular eye diseases. The polyethylene glycol-modified angiogenesis inhibitor disclosed by the present invention is prepared by a synthetic method.
A polyethylene glycol-modified angiogenesis inhibitor HM-1, comprising the sequence of mPEG-Arg-Gly-Ala-Asp-Arg-Ala-Gly-Gly-Gly-Gly-Arg-Gly-Asp (SEQ ID NO:
Dependencies are inferred from the claim text.